Jury says Bayer should pay $80 million to man in Roundup most cancers trial
The Bayer AG emblem sits behind silhouetted members of the administration board through the firm’s annual normal assembly in Bonn, Germany, Might 25, 2018.
A U.S. jury on Wednesday awarded $80 million to a person who claimed his use of Bayer’s glyphosate-based weed killer Roundup prompted his most cancers, within the newest authorized setback for the corporate dealing with hundreds of comparable lawsuits.
The jury in San Francisco federal court docket stated the corporate was accountable for plaintiff Edwin Hardeman’s non-Hodgkin’s lymphoma.
It awarded $5 million in compensatory damages and $75 million in punitive damages to Hardeman after discovering that Roundup was defectively designed, that Monsanto did not warn of the herbicide’s most cancers threat and that the corporate acted negligently.
Bayer purchased Roundup maker Monsanto final 12 months for $63 billion.
The corporate denies the allegations, saying many years of research by impartial scientists have proven glyphosate and Roundup to be protected for human use.
The trial is simply the second of greater than 11,200 Roundup lawsuits set to go to trial in america. Earlier litigation setbacks and a previous jury verdict in opposition to the corporate have despatched Bayer shares plunging.
The decision comes roughly per week after the identical jury on March 19 discovered Roundup to have been a “substantial issue” in inflicting Hardeman’s most cancers, permitting the trial to proceed right into a second part to find out legal responsibility and damages. Bayer shares fell greater than 12 p.c after final week’s jury discovering.
Official correction: This story has been up to date to mirror that the jury awarded over $80 million to the person, together with $5 million in compensatory damages. Reuters misstated the figures in a earlier model of its story.